Mir-122 inhibitor for the treatment of hepatitis C virus (HCV) infection or hyperlipidemia or hypercholesterolemia or for the prevention or treatment of atherosclerosis, wherein said miR-122 inhibitor is a 5 'sequence antisense oligonucleotide -CcAttGTcaCaCtCC-3 ', and in which the lowercase letters represent DNA, the uppercase letters represent ANB and all C of ANB are 5'-methyl-cytosine and all internucleoside bonds are phosphorothioate bonds, and in which the inhibitor of miR-122 should be used in combination with an additional VLDL assembly inhibitor that is either an antisense oligomeric compound comprising a nucleobase sequence that is complementary to a corresponding region of the apoB-100 mRNA or a hypocholesterolemic compound selected from the group that consists of bile salt sequestering resins (for example, cholestyramine, colestipol and colesevelam hydrochloride), reduced HMGCoA inhibitors a (for example, lovastatin, cerivastatin, prevastatin, atorvastatin, simvastatin and fluvastatin), nicotinic acid, derivatives of fibric acid (for example, clofibrate, gemfibrozil, fenofibrate, bezafibrate and ciprofibrate), probucol, neomycin, vegetable dextrotyroxyl esters , cholesterol absorption inhibitors (eg, ezetimibe), implitapide, inhibitors of bile acid transporters (apical sodium dependent bile acid transporters), hepatic CYP7a regulators, estrogen replacement therapeutic agents (eg tamoxifen) , anti-inflammatories (eg glucocorticoids) and statins.Inhibidor de mir-122 para el tratamiento de infección por virus de la hepatitis C (VHC) o hiperlipidemia o hipercolesterolemia o para la prevención o el tratamiento de aterosclerosis, en el que dicho inhibidor de miR-122 es un oligonucleótido antisentido de secuencia 5&rsquo；-CcAttGTcaCaCtCC-3&rsquo；, y en el que las letras minúsculas representan ADN, las letras mayúsculas representan ANB y todas las C de ANB son 5&rsquo；-metil-citosina y todos los enlaces internucleosídicos son enlaces fosforotioato, y en el que e
